2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Inflammation
1
Cognitive Dysfunction
1
Chemotherapy-Related Cognitive Impairment
1
Autoimmune Diseases
1
Interventions
Exercise
6
Transcranial Direct Current Stimulation
4
Neuropsychological Tests
4
Walking
3
Memantine
3
Tablets
2
Standard of Care
2
Patient Reported Outcome Measures
2
Methods
2
Electroencephalography
2
Drug Therapy
2
Donepezil
2
Cognitive Behavioral Therapy
2
mazdutide
1
lithium sulfate
1
lime
1
fasudil
1
enzalutamide
1
blueberry extract
1
beta Carotene
1
acetaminophen, aspirin, caffeine drug combination
1
XENP 1595
1
Vitamin E
1
Vitamin D
1
Ultraviolet Therapy
1
Transcranial Magnetic Stimulation
1
Time
1
Therapeutics
1
Tai Ji
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cognitive Dysfunction
×
Ashwagandha
×
Clear all
NCT04092647
2023-06-15
Ashwagandha for Cognitive Dysfunction
Sutter Health
Phase 2
Unknown
80 enrolled